Abdominal aortic aneurysm (AAA) is a lethal cardiovascular disease, and there is no proven
drug treatment for this condition. In this study, by using the Connectivity Map (CMap) …

Background Identifying effective drugs to suppress vascular inflammation is a promising
strategy to delay the progression of abdominal aortic aneurysm (AAA). Itaconate has a vital …

Background: Abdominal aortic aneurysm (AAA) is a severe aortic disease with a high
mortality rate in the event of rupture. Pharmacological therapy is needed to inhibit AAA …

Abstract Context Previously, we found Alisma orientalis beverage (AOB), a classic traditional
Chinese medicine (TCM) formulation, had the potential effect of treating atherosclerosis …

Background and aims Inflammation, oxidative stress, matrix degradation, medial calcification
and vascular smooth muscle cell (VSMC) loss are prominent features in abdominal aortic …

Abdominal Aortic aneurysm (AAA) is associated with chronic inflammation, cells apoptosis,
and impairment of autophagy. BP-1-102, a novel potent STAT3 inhibitor, has been recently …

Introduction: Aortic aneurysm is a life-threatening disease resulted from progressive
dilatation of the aorta, which can be subdivided into thoracic and abdominal aortic …

Abdominal aortic aneurysm (AAA) is a serious vascular disease with high mortality. Our
previous study suggested that hyperhomocysteinemia (HHcy) exaggerates the occurrence …

Abdominal aortic aneurysm (AAA) affects more than 5% of the population in developed
countries and the pharmacotherapies for AAA are limited. Here, we explored whether …

Although the pathogenesis of abdominal aortic aneurysm (AAA) remains unclear, evidence
is accumulating to support a central role for inflammation. Inflammatory responses are …